tradmap

IMMX Earnings Immix Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 -$0 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$29M -$15M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-163% -69% 24% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$12M -$6M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-142% -71% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–17 of 17
Q2 20262026-06-30-0.362026-08-0710-Q
Q1 20262026-03-31-0.182026-05-0710-Q
FY 20252025-12-31-0.892026-03-2510-K
Q3 20252025-09-30-0.612025-11-0710-Q
Q2 20262025-06-30-0.372026-08-0710-Q
Q1 20262025-03-31-0.152026-05-0710-Q
FY 20252024-12-31-0.762026-03-2510-K
Q3 20252024-09-30-0.602025-11-0710-Q
Q2 20252024-06-30-0.362025-08-0810-Q
Q1 20252024-03-31-0.222025-05-0810-Q
FY 20242023-12-31-0.892025-03-2510-K
Q3 20242023-09-30-0.652024-11-1210-Q
Q2 20242023-06-30-0.422024-08-1210-Q
Q1 20242023-03-31-0.182024-05-0910-Q
FY 20232022-12-31-0.592024-03-2910-K
Q3 20232022-09-30-0.322023-11-1310-Q
Q2 20232022-06-30-0.212023-08-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.